Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Recruiting2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05773274Phase 2Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT03375320Phase 3Active Not Recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT07150546Phase 1Recruiting

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Showing all 3 trials

Research Network

Activity Timeline